Antiviral drug utilization and annual expenditures for patients with chronic HBV infection in Guangzhou, China, in 2008-2015.

Abstract

BACKGROUND:

The aims of this study were to describe antiviral drug (AD) utilization and costs in patients with chronic HBV infection.

METHODS:

We conducted a retrospective study of patients in the hospital and calculated annual proportions of AD utilization and costs among patients. A two-part model was used to estimate adjusted odds ratio (OR) for antiviral therapy and cost ratios for antiviral costs associated with demographics.

RESULTS:

Of a total of 14,920 records, 143,658 records were involved in the analysis. The annual proportions of AD utilization were 56.99% (45.65%) for inpatients (outpatients) during 2008-2015 and increased annually. Entecavir (ETV), in particular, increased from 11.08% to 70.26% (11.05% to 49.35%) for inpatients (outpatients). The patients with medical insurance were more likely to use AD than patients without insurance, and the adjusted OR was 1.11 (95% CI: 1.03, 1.19) for inpatients and 1.66 (1.59, 1.73) for outpatients. With the disease progressing, the proportion of antiviral costs in total direct medical costs decreased from 13.91% to 4.07% (71.29% to 49.29%) for inpatients (outpatients).

CONCLUSIONS:

The use of AD for chronic HBV infection was less than expected based on established guidelines, and only half of patients received antiviral treatment. However, the AD utilization, especially ETV, increased annually. Reimbursement policy was the most important factor affecting antiviral treatment. Antiviral therapy was an important part of the direct medical costs, especially in the early stage of disease.

• Authors: Feng Zhou, Weidong Jia, Shuo Yang, Ge Chen, Guanhai Li, Yueping Li, Yingfang Liang, Yi Yang, Yanhui Gao, Yue Chen
• Journal: Antiviral therapy (Antivir Ther) Vol. 24 Issue 6 Pg. 405-416 ( 2019) ISSN: 2040-2058 [Electronic] England
• PMID: 31348006 (Publication Type: Historical Article, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antiviral Agents

Topics

• Antiviral Agents (economics, therapeutic use)
• China (epidemiology)
• Drug Costs
• Drug Utilization (economics)
• Female
• Health Expenditures
• Hepatitis B virus (drug effects)
• Hepatitis B, Chronic (drug therapy, epidemiology, history, virology)
• History, 21st Century
• Humans
• Liver Neoplasms (epidemiology, etiology)
• Male
• Models, Theoretical
• Public Health Surveillance